Трансплантация почки и гиперпаратиреоз
https://doi.org/10.23873/2074-0506-2017-9-2-137-152
Аннотация
Ключевые слова
Об авторе
О. Н. Ветчинникова
ГБУЗ МО МОНИКИ им. М.Ф. Владимирского
Россия
Россия
д-р мед. наук, старший научный сотрудник хирургического отделения трансплантологии и диализа МОНИКИ им. М.Ф. Владимирского, Москва, Россия
Список литературы
1. Cunningham J., Locatelli F., Rodriguez M. Secondary Hyperparathyroidism: Pathogenesis, Disease Progression and Therapeutic Options. Clin. J. Am. Soc. Nephrol. 2011;6(4):913– 921. PMID:21454719 DOI:10.2215/CJN.06040710
2. Jamal S.A., Miller P.D. Secondary and Tertiary Hyperparathyroidism. J. Clin. Densitometry: Assessment of Skeletal Health. 2013;16(1):64–68. PMID:2326774 DOI:101016/j.jocd.2012.11.012
3. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin. Nephrol. 2013;33(2):191–203. PMID:23465505 DOI:10.1016/j.semnephrol.2012.12.019
4. Ветчинникова О.Н., Шестеро Е.В., Егорова Е.А. Минерально-костные нарушения у реципиентов почечного трансплантата. Нефрология. 2016;20(6):49–56. DOI:10.24884/1561-6274-2016-6-49-56
5. Perrin P., Caillard S., Javier R.M. Et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am. J. Transplant. 2013;13(10):2653–2663. PMID:24034142 DOI:10.1111/ajt.12425
6. Wolf M., Weir M.R., Kopyt N. et al. Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016;100(1):184–189. PMID:26177089 DOI:10.1097/TP.0000000000000823
7. Tillmann F.-P., Wächtler C., Hansen A. et al. Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years. Transplantation Research. 2014;3(3):21–26. PMID:25606342 DOI:10.1186/s13737-014-0021-5
8. Grethen E., Hill K.M., Jones R., Cacucci B.M. et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J. Clin. Endocrinol. Metab. 2012;97(5):1655–1662. PMID:22362819 DOI:10.1210/jc.2011-2280
9. Ермоленко В.М., Волгина Г.В., Михайлова Н.А. и др. Лечение минеральных и костных нарушений при хронической болезни почек. Нефрология. Клинические рекомендации. Ред.: Шилов Е.М., Смирнов А.В., Козловская Н.Л. М.: ГЭОТАР-Медиа, 2016. 687–709.
10. Bleskestad I.H., Bergrem H., Leivestad T. et al. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin. Transplant. 2014;28:479–486. PMID:25649861 DOI:10.1111/ctr12341
11. Evenepoel P., Claes K., Kuypers D. et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A singlecentre study. Nephrol. Dial. Transplant. 2004;19(5):1281–1287. PMID:14993493 DOI:10.1093/ndt/gfh128
12. Scillitani A., Guarnieri V., De Geronimo S. et al. Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor. J. Clin. Endocrinol.Metab. 2004;89(11):5634–5638. PMID:15531522 DOI:10.1210/jc.2004-0129
13. Weidong W., Chunling L. Reduce expression of renal Na+ transporter in rats with PTH-induced hypercalcemia. Am. J. Physiol. Renal. Physiol. 2004;286(3):534–545. PMID:14625199 DOI:10.1152/ajprenal.00044.2003
14. D’Marco L., Bellasi A., Mazzaferro S., Raggi P. Vascular calcification, bone and mineral metabolism after kidney transplantation. World J. Transplant. 2015;5(4):222–230. DOI:10.5500/wjt.v5.i4.222
15. Egbuna O.I., Taylor J.G., Bushinsky D.A., Zand M.S. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin. Transplant. 2007;21(4):558–566. PMID:17645720 DOI:10.1111/j.1399-0012.2007.00690.x
16. Kawarazaki H., Shibagaki Y., Fukumoto S. et al. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study. Ther. Apher. Dial. 2011;15(5):481–487. PMID:21974702 DOI:10.1111/j.1744-9987.2011.00932.x
17. Bleskestad I.H., Thorsen I.S., Jonsson G. et al. Soluble Klotho and intact fibroblast growth factor 23 in longterm kidney transplant patients. Eur. J. Endocrinol. 2015;172(4):343–350. PMID: 25572388 DOI:10.1530/EJE-14-0457
18. Tomida K., Hamano T., Ichimaru N. et al. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation. Bone. 2012;51(4):729–736. PMID:2796419 DOI:10.1016/j.bone.2012.06.027
19. Hiemstra T.F., Brown A.J., Chaudhry A.N., Walsh M. Association of calcium, phosphate and parathyroid hormone with renal allograft function: a retrospective cohort study. Am. J. Nephrol. 2013;37(4):339–345. PMID:23548209 DOI:10.1159/000348376
20. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009;113:S1–S130. PMID:19644521 DOI:10.1038/ki.2009.188
21. Alshayeb H.M., Josephson M.A., Sprague S.M. CKD – Mineral and Bone Disorder Management in Kidney Transplant Recipients. Am. J. Kidney Dis. 2013;61(2):310–325. PMID:23102732 DOI:10.1053/j.ajkd.2012.07.022
22. Ketteler M., Elder G.J, Evenepoel P. et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015(3);87:502–528. PMID:25651364 DOI:10.1038/ki.2014.425
23. Naylor K.L., Zou G., Leslie W.D. et al. Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a populationbased cohort study. Canadian Journal of Kidney Health and Disease. 2016;3(3):2– 9. PMID:26779343 PMCID:PMC4715326 DOI:10.1186/s40697-016-0092-y
24. Naylor K.L., Jamal S.A., Zou G.Y. Et al. Fracture incidence in adult kidney transplant recipients. Transplantation. 2016;100(1):167–175. PMID:26154389 DOI:10.1097/TP.0000000000000808
25. Nishiyama K.K., Pauchard Y., Nikkel L.E. et al. Longitudinal HR-pQCT and Image Registration Detects Endocortical Bone Loss in Kidney Transplantation Patients. Journal of Bone and Mineral Research. 2015;30(3):554–561. PMID:25213758 DOI:10.1002/jbmr.2358
26. Методы визуализации околощитовидных желез и паратиреоидная хирургия: руководство для врачей. Под ред. А.П. Калинина. Москва: Издательский дом Видар-М, 2010. 311 с.
27. Захарова Н.М., Ветчинникова О.Н., Иванцова Л.П. Цитологическая диагностика гиперпаратиреоза. Клиническая лабораторная диагностика. 2014;59(12):36–40.
28. Захарова Н.М., Ветчинникова О.Н., Иванцова Л.П. Цитоморфологические особенности паращитовидных желез при различных формах гиперпаратиреоза. Клиническая лабораторная диагностика. 2016;61(10):697–700.
29. Kievit A.J., Tinnemans J.G.M., Idu M.M. et al. Outcome of Total Parathyroidectomy and Autotransplantation as Treatment of Secondary and Tertiary Hyperparathyroidism in Children and Adults. World J. Surg. 2010;34(5):993–1000. PMID:20145928 PMCID:PMC2848726 DOI 10.1007/s00268-010-0446-z
30. Park J.H., Kang S.-W., Jeong J.J. et al. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: A 31-year experience in a single institution. Endocrine Journal. 2011;58(10):827–833. PMID:21804261
31. Lou I., Schneider D.F., Leverson G. Et al. Parathyroidectomy is underused in patients with tertiary hyperparathyroidism after renal transplantation. Surgery. 2016;159(1):172–179. PMID:26603850 PMCID:PMC4688142 DOI:10.1016/j.surg.2015.08.039
32. Ferreira G.F., Montenegro F.L.M., Machado D.J. et al. Parathyroidectomy after kidney transplantation: shortand long- term impact on renal function. CLINICS. 2011;66(3): 431–435. PMID:21552668
33. Akaberi S., Clyne N., Sterner G. Et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991–2009. BMC Nephrol. 2014;15:75–81. PMID:24886448PMCI DOI:10.1186/1471-2369-15-75.
34. Dewberry L.K., Weber C., Sharma J. Near total parathyroidectomyn is effective therapy for tertiary hyperparathyroidism. Am. Surg. 2014;80(7):646–651. PMID:24987894
35. Messa P., Regalia A., Alfieri C.M. et al. Current indications to parathyroidectomy in CKD patients before and after transplantation. J. Nephrol. 2013;26(6):1025–1032. PMID:24284524 DOI:10.5301/jn.5000277
36. Torregrosa J.V., Barros X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013;33(6):751– 757. PMID:24241361 DOI:10.3265/Nefrologia.pre2013.Aug.11888
37. Yang R.L., Freeman K., Reinke C.E. et al. Tertiary Hyperparathyroidism in kidney transplant recipients: Characteristics of patients selected for different treatment strategies. Transplantation. 2012;94(1):70–76. PMID:22706321 DOI:10.1097/TP.0b013e3182530699
38. Martin T.J. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J. Clin. Invest. 2005;115(9):2322–2324. PMID:16138187 PMC1193889 DOI:10.1172/JCI26239
39. Hsieh T.M., Sun C.K., Chen Y.T., Chou F.F. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am. Surg. 2012;78(5):600–606. PMID:22546135
40. Miao D., He B., Jiang Y. et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 2005;115(9):2402–2411. PMID:16138191 PMCID:PMC1193882 DOI:10.1172/JCI24918
41. Sadideen H.M., Taylor J.D., Goldsmith D.J. Total parathyroidectomy without autotransplantation after renal transplantation for tertiary hyperparathyroidism: long-term follow-up. Int. Urol. Nephrol. 2012;44(1):275–281. PMID:21997202 DOI:10.1007/s11255-011-0069-9
42. Schlosser K., Rothmund M., Maschuw K. et al. Graft-dependent Renal Hyperparathyroidism Despite Successful Kidney Transplantation. World J. Surg. 2008;32(4):557–565. PMID:18204949 DOI:10.1007/s00268-007-9337-3
43. Pitt S.C., Panneerselvan R., Chen H., Sippel R.S. Secondary and Tertiary Hyperparathyroidism: The Utility of ioPTH Monitoring. World J. Surg.2010;34(6):1343–1349. PMID:20386902 PMCID:PMC290574 DOI:10.1007/s00268-010-0575-4
44. Nogueira E.L., Costa A.C., Santana A. et al. Teriparatide efficacy in the treatment of severe hypocalcemia after kidney transplantation in parathyroidectomized patients: a series of five case reports. Transplantation. 2011;92(3):316– 320. PMID:21694663 DOI:10.1097/TP.0b013e3182247b98
45. Schwarz A., Rustien G., Merkel S. et al. Decreased renal transplant function after parathyroidectomy. Nephrol. Dial. Transplant. 2007;22(2):584–591. PMID:17035377 DOI:10.1093/ndt/gfl583
46. Schlosser K., Endres N., Celik I. et al. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J. Surg. 2007;31(10):1947–1953. PMID:17665243 DOI:10.1007/s00268-007-9187-z
47. Kalantar-Zadeh K., Molnar M.Z., Kovesdy C.P. et al. Management Mineral and Bone Disorder after Kidney Transplantation. Curr. Opin. Nephrol. Hypertens. 2012;21(4):389–403. PMID:22614626 DOI:10.1097/MNH.0b013e3283546ee0
48. Courbebaisse M., Alberti C., Colas S. et al. VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. Trials. 2014;15:430–443. PMID:25376735 PMCID:PMC4233037 DOI:10.1186/1745-6215-15-430
49. Amer H., Griffin M.D., Stegall M.D. Et al. Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial. Am. J. Transplant. 2013;13:1576–1585. PMID:23601186 DOI:10.1002/ajt.12227
50. Gonzalez E., Rojas-Rivera J., Polanco N. et al. Effects of Oral Paricalcitol on Secondary Hyperparathyroidism and Proteinuria of Kidney Transplant Patients. Transplantation. 2013;95(7):e49–e52. PMID:23545517 DOI:10.1097/TP.0b013e3182855565
51. Pérez V., Sánchez-Escuredo A., Lauzurica R. et al. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. Eur. J. Pharmacol. 2013;709(1–3):72–79. PMID:23567070 DOI:10.1016/j.ejphar.2013.03.040
52. Trillini M., Cortinovis M., Ruggenenti P. et al. Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. J. Am. Soc. Nephrol. 2015;26(5):1205–1214. PMID:25194004 DOI:10.1681/ASN.2013111185
53. Borrego Utiel F.J., Bravo Soto J.A., Merino Pérez M.J. et al. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with se condary hyperparathyroidism. Nefrologia. 2015;35(4):363–373. PMID:26306956 DOI:10.1016/j.nefro.2015.06.018
54. Ветчинникова О.Н., Кантария Р.О. Терапевтическая тактика при третичном гиперпаратиреозе после трансплантации почки (обзор литературы и клинические наблюдения). Клиническая нефрология. 2014;1:55–63.
55. Ветчинникова О.Н., Щербакова Е.О., Полякова Е.Ю. Цинакальцет в лечении гиперпаратиреоза у реципиентов почечного трансплантата. Вестник трансплантологии и искусственных органов. 2014;16(1):47– 53. DOI:10.15825/1995-1191-2014-1-47-53
56. Thiem U., Alois Gess A., Borchhardt K. Long-Term Clinical Practice Experience with Cinacalcet for Treatment of Hypercalcemic Hyperparathyroidism after Kidney Transplantation. BioMed Research International. 2015; 2015: 12 p. ID 292654. Режим доступа: https://www.hindawi.com/journals/bmri/2015/292654/ DOI:10.1155/2015/292654
57. Okada M., Tominaga Y., Izumi K. et al. Tertiary Hyperparathyroidism Resistant to Cinacalcet Treatment. Ther. Apher. Dial. 2011;15(Suppl 1):33–37. PMID:21595850 DOI:10.1111/j.1744-9987.2011.00924.x
58. Cohen J.B., Gordon C.E., Balk E.M., Francis J.M. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation. 2012;94(10):1041–1048. PMID:23069843 DOI:10.1097/TP.0b013e31826c3968
59. Evenepoel P., Cooper K., Holdaas H. et al. A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. Am. J. Transplant. 2014;14(11):2545–2555. PMID:25225081DOI:10.1111/ajt.12911
Рецензия
Для цитирования:
Ветчинникова О.Н. Трансплантация почки и гиперпаратиреоз. Трансплантология. 2017;9(2):137-152. https://doi.org/10.23873/2074-0506-2017-9-2-137-152
For citation:
Vetchinnikova O.N. Kidney transplantation and hyperparathyroidism. Transplantologiya. The Russian Journal of Transplantation. 2017;9(2):137-152. https://doi.org/10.23873/2074-0506-2017-9-2-137-152
Просмотров: 799
Послать статью по эл. почте 